Vendor comparison · 2026
DSIP vendors: 25 compared on COAs and price
Tissue & recoveryAlso known as Delta sleep-inducing peptide
Evidence tier
Multiple human trials
3 human trials · 1 observational
- Vendors carrying it
- 25
- 21 with a listed price
- Vendors with checkable COAs
- 15
- 16 publish any certificate
- Lots tested
- 18
- 17 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 18 Sept 2026
- oldest 28 Apr 2025
- Laboratories named
- 7
- most often Freedom Diagnostics Testing
- Median label gap
- 7.1%
- 28% of lots within 5% of label
- Median purity
- 99.72%
- 18 of 18 lots at 99% or above
- Lowest price per mg
- $3.00
- peer median $7.00
- Publications located
- 519
- researched since 1975
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable DSIP testing in this index: 2 lots assayed by ILS Laboratories, the newest on 14 Aug 2026. The lowest listed price is $3.00 per mg at Eternal Peptides, against a peer median of $7.00. 25 vendors carrying DSIP are compared below. 15 publish at least one certificate naming a checkable laboratory, 18 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying DSIP
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 99.6% | 3.5% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | — | 2 / 2 | ILS Laboratories | 99.9% | 7.1% | ||
| 3 | PeptidePlugs | 91.394% | $4.00 (57%) | 2 / 2 | Freedom Diagnostics Testing | 99.3% | 12.1% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 88.498% | $6.00 (86%) | 1 / 1 | ILS Laboratories | 99.5% | 4.4% | ||
| 5 | One Aminos | 87.589% | $5.00 (71%) | 1 / 1 | United Laboratories | 99.7% | 0.2% | ||
| 6 | Ascend ScienceISO/IEC 17025 | 86.494% | $7.00 (100%) | 1 / 1 | Kovera Labs and/or ILS Labs | 99.7% | 9.8% | ||
| 7 | Ascension Peptides | 84.389% | $6.00 (86%) | 1 / 1 | MZ Biolabs | 99.7% | 36.8% | ||
| 8 | Modern AminosISO/IEC 17025COAs need an account | 80.997% | $7.00 (100%) | 1 / 1 | Freedom Diagnostics Testing | 99.4% | 3.2% | ||
| 9 | Evo Labs Research | 79.387% | $4.00 (57%) | 0 / 1 | Not named | 99.4% | 11.2% | ||
| 10 | Simple Peptide | 79.192% | $7.00 (100%) | 1 / 1 | Freedom Diagnostics Testing | 99.7% | 19.0% | ||
| 11 | NeuroLabs Research | 76.891% | $8.39 (120%) | 1 / 1 | Freedom Diagnostics Testing | 99.2% | 7.2% | ||
| 12 | Bench Grade Peptides | 76.189% | $8.60 (123%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Northline LabsISO/IEC 17025 | 73.595% | — | 1 / 1 | ILS Laboratories | 99.9% | 7.0% | ||
| 14 | Hydro Research PeptidesISO/IEC 17025 | 7289% | $10.00 (143%) | 1 / 1 | Janoshik Analytical | 99.9% | 1.4% | ||
| 15 | Eternal Peptides | 6963% | $3.00 (43%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Good Science Bio | 67.571% | $7.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Mile High Compounds | 66.291% | $5.00 (71%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Protide HealthAge-gated COAs | 65.192% | $12.00 (171%) | 1 / 1 | Freedom Diagnostics Testing | 100.0% | 11.9% | ||
| 19 | Licensed Peptides | 62.787% | $10.80 (154%) | 1 / 1 | Vanguard Laboratory | 99.8% | 5.8% | ||
| 20 | True Research Labs | 61.468% | $7.90 (113%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Evolve Peptides | 59.768% | $9.00 (129%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Improved Peptides | 57.487% | $10.40 (149%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Biotech Peptides | 5760% | $8.80 (126%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.0% | 7.0% | ||
| 25 | BioLongevity Labs | 55.572% | $11.19 (160%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of DSIP is on file. All 18 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
18 of 18 lots at 99% or above; median 99.72%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 7 |
| ≥99.5% | 11 |
28% of lots within 5% of the labelled mass; median gap 7.1%.
| Range | lots |
|---|---|
| ≤2% | 2 |
| 2–5% | 3 |
| 5–10% | 7 |
| 10–20% | 5 |
| >20% | 1 |
21 vendors, $3.00 to $12.00; median $7.00.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 1 |
| $4.00–$6.00 | 4 |
| $6.00–$8.00 | 7 |
| $8.00–$10.00 | 4 |
| $10.00–$12.00 | 5 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 8 | 7 | 44% | Public lookup |
| ILS LaboratoriesUS | 4 | 3 | 22% | Public lookup |
| Janoshik AnalyticalCZ | 1 | 1 | 6% | Public lookup |
| Kovera Labs and/or ILS Labs | 1 | 1 | 6% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 6% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 6% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 6% | No public lookup found |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1975 — 51 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
519 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 18 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.28 pts purity across lots, mean label deviation 9.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
25 of 25 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
17 of 18 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is DSIP?
Delta sleep-inducing peptide, a nine–amino-acid peptide first isolated from cerebral blood, studied in relation to sleep regulation and stress responses.
Studied in published research for sleep regulation and stress resilience.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and small human investigations of sleep physiology, with mixed findings. PepIndex does not evaluate clinical significance and does not describe administration.
- Delta sleep-inducing peptide — European journal of anaesthesiology (2001)
Peer-reviewed article indexed in PubMed, published in European journal of anaesthesiology (2001).
- Delta-sleep-inducing peptide (DSIP): a review — Neuroscience and biobehavioral reviews (1984)
Peer-reviewed article indexed in PubMed, published in Neuroscience and biobehavioral reviews (1984).
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle — Journal of neurochemistry (2006)
Peer-reviewed article indexed in PubMed, published in Journal of neurochemistry (2006).
- Delta-sleep-inducing peptide (DSIP): an update — Peptides (1986)
Peer-reviewed article indexed in PubMed, published in Peptides (1986).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity? — Obesity reviews : an official journal of the International Association for the Study of Obesity (2009)
Peer-reviewed article indexed in PubMed, published in Obesity reviews : an official journal of the International Association for the Study of Obesity (2009).
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke — Molecules (Basel, Switzerland) (2021)
Peer-reviewed article indexed in PubMed, published in Molecules (Basel, Switzerland) (2021).
- [Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide] — Medicinski pregled (2008)
Peer-reviewed article indexed in PubMed, published in Medicinski pregled (2008).
Indexed studies4 human-evidence of 4
- DSIP in insomnia — Human — controlled trial, 1984
This paper summarizes different investigations into effects of delta sleep-inducing peptide (DSIP) injections on insomnia. Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep. Repeated administrations indicated a buildup with normalization of sleep structure after four administrations. Repeated injections in the morning - besides increasing daytime activity - still had a strong positive effect on night sleep, but not s…
- Effects of DSIP on narcolepsy — Case report, 1984
Repeated injections of delta sleep-inducing peptide (DSIP) were given to a 35-year-old male narcoleptic. Effects on wakefulness and sleep were evaluated by self-reports, performance tests, multiple sleep latency test and all-night polysomnography. DSIP reduced the frequency of sleep attacks and increased activity, alertness and performance during day-time. The sleep period was compressed by DSIP with enhancement of REM sleep. The results suggest that the effects are due to an…
- A clinical trial with DSIP — Human — controlled trial, 1984
In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months. The mood and performance during the daytime improved as well. A problem may be a long-standing habit of drug addiction.
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Human — controlled trial, 1987
Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placeb…
Evidence digest
What the research on DSIP actually shows
The indexed literature on DSIP includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether DSIP is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.